These initial findings suggest that the combination treatment effectively triggered tumor-specific CTL responses and inhibited tumor growth in vivo, with increased infiltration of mature DC and CD8+ T cells, the main effector cells in the local anti-tumor response. The gene discussed is CD8A; the disease is neoplasm.